Expression of brdU in BBN induced rat bladder tumor.
- Author:
Wun Jae KIM
1
;
Hyung Geun SONG
;
Young Kyoon KIM
Author Information
1. Department of Urology, College of Medicine, Chungbuk National University, Cheongju, Korea.
- Publication Type:Original Article
- Keywords:
BBN;
Bladder tumor;
Bomodeoxyuridine (BrdU);
Labeling index
- MeSH:
Animals;
Bromodeoxyuridine*;
Carcinogenesis;
Cell Cycle;
DNA;
Hyperplasia;
Rats*;
S Phase;
Thymidine;
Urinary Bladder Neoplasms*;
Urinary Bladder*
- From:Korean Journal of Urology
1993;34(1):1-6
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
We labeled-S-phase cell in BBN induced rat bladder tumors using anti-bromodeoxyuridine anti- body. The thymidine analogue, bromodeoyuridine (BrdU), was incorporated into DNA during the S -phase or the cell cycle. Anti-BrdU monoclonal antibody can be detected by the immunohistochemical method for an in vivo labeling study. Sequential cellular change (normal, simple hyperplasia, nodular or papillary hyperplasia, and transitional cell carcinoma-Ta, T1) was observed in rat urinary bladder according to the duration of BBN administration. The BrdU labeling index, S phase fraction, was determined by counting the number of BrdU labeled cells in the tissue section. The average labeling index obtained using this method in normal, simple hyperplasia(SH), nodular or papillary hyperplasia(NPH), and bladder tumor (Ta. T1) was 1.7, 5.6, 11.2, and 18.9 (14.9, 21.9), respectively. Also, the higher S phase fraction was found in grade II than in grade I .The higher S phase fraction indicated greater biological malignancy based on the fact that mean labeling index progressively increased with tumorigenesis. However, mean labeling index at NPH did not significantly differ from that of Ta, which implies that NPH might represent the similar cellular characteristics.
